Literature DB >> 12113395

The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in japanese patients with advanced non-small-cell lung cancer.

T Matsumoto1, Y Ohashi, S Morita, K Kobayashi, M Shibuya, Y Yamaji, K Eguchi, M Fukuoka, K Nagao, Y Nishiwaki, H Niitani.   

Abstract

The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD), which consists of four domains (functional, physical, mental, and psychosocial) and a global face scale, was developed as a generic questionnaire for Japanese cancer patients undergoing chemotherapy. We examined the validity and reliability of this questionnaire in Japanese patients with advanced non-small-cell lung cancer (NSCLC), who participated in two randomized phase III trials. After excluding two items, one showing low test-retest reliability and the other showing poor convergent validity for the target population, Cronbach's alpha coefficients ranged from 0.795 to 0.897 and the intra-class correlation coefficients ranged from 0.612 to 0.866. These results confirmed the high reliability of the questionnaire. The results of factor analysis provided strong support for the domain structure used in the questionnaire. Each of the four domains had a moderate to strong association with important clinical variables, such as performance status or weight loss, and correlation analysis showed that the face scale provided an appropriate measure of the global quality of life. These results indicated that the QOL-ACD is potentially useful for clinical research on Japanese patients with advanced NSCLC.

Entities:  

Mesh:

Year:  2002        PMID: 12113395     DOI: 10.1023/a:1015614505929

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  21 in total

Review 1.  Quality of life end points in cancer clinical trials: review and recommendations.

Authors:  C M Moinpour; P Feigl; B Metch; K A Hayden; F L Meyskens; J Crowley
Journal:  J Natl Cancer Inst       Date:  1989-04-05       Impact factor: 13.506

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Assessing the quality of life of patients with cancer: east meets west.

Authors:  N K Aaronson
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

4.  A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer.

Authors:  K Kobayashi; F Takeda; S Teramukai; I Gotoh; H Sakai; S Yoneda; Y Noguchi; H Ogasawara; K Yoshida
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

5.  Assessment of quality of life in clinical trials of the British Medical Research Council.

Authors:  D Machin
Journal:  J Natl Cancer Inst Monogr       Date:  1996

6.  A modular approach to quality-of-life assessment in cancer clinical trials.

Authors:  N K Aaronson; M Bullinger; S Ahmedzai
Journal:  Recent Results Cancer Res       Date:  1988

7.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

8.  Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese.

Authors:  H Fumimoto; K Kobayashi; C H Chang; S Eremenco; Y Fujiki; S Uemura; Y Ohashi; S Kudoh
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

9.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.

Authors:  H Schipper; J Clinch; A McMurray; M Levitt
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

10.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

View more
  8 in total

1.  Analysis of incomplete quality of life data in advanced stage cancer: a practical application of multiple imputation.

Authors:  Satoshi Morita; Kunihiko Kobayashi; Kenji Eguchi; Taketoshi Matsumoto; Masahiko Shibuya; Yasufumi Yamaji; Yasuo Ohashi
Journal:  Qual Life Res       Date:  2005-08       Impact factor: 4.147

2.  Validation of the care notebook for measuring physical, mental and life well-being of patients with cancer.

Authors:  Kunihiko Kobayashi; Joseph Green; Mari Shimonagayoshi; Noriaki Kanemoto; Ryo Kasai; Yoichi Itoh; Yuki Fujiki; Yasuo Ohashi; Carolyn Gotay; Shoji Kudoh
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

Review 3.  Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences.

Authors:  Alison Rowsell; Samantha C Sodergren; Vassilios Vassiliou; Anne-Sophie Darlington; Marianne G Guren; Bilal Alkhaffaf; Chantelle Moorbey; Kristopher Dennis; Mitsumi Terada
Journal:  Gastric Cancer       Date:  2022-06-11       Impact factor: 7.701

4.  Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).

Authors:  Nobuyuki Katakami; Junji Uchino; Takuma Yokoyama; Tateaki Naito; Masashi Kondo; Kouzo Yamada; Hiromoto Kitajima; Kozo Yoshimori; Kazuhiro Sato; Hiroshi Saito; Keisuke Aoe; Tetsuya Tsuji; Yuichi Takiguchi; Koichi Takayama; Naoyuki Komura; Toru Takiguchi; Kenji Eguchi
Journal:  Cancer       Date:  2017-12-04       Impact factor: 6.860

5.  Incremental patient care program decreases anxiety, reduces depression and improves the quality of life in patients with colorectal cancer receiving adjuvant chemotherapy.

Authors:  Jiaying Li; Xuesong Liu
Journal:  Exp Ther Med       Date:  2019-08-13       Impact factor: 2.447

6.  The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.

Authors:  Youssef Ben Bouazza; Jan P Van Meerbeeck
Journal:  Transl Lung Cancer Res       Date:  2018-10

7.  Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.

Authors:  Koichi Takayama; Nobuyuki Katakami; Takuma Yokoyama; Shinji Atagi; Kozo Yoshimori; Hiroshi Kagamu; Hiroshi Saito; Yuichi Takiguchi; Keisuke Aoe; Akira Koyama; Naoyuki Komura; Kenji Eguchi
Journal:  Support Care Cancer       Date:  2016-03-23       Impact factor: 3.603

8.  Efficacy and Safety of Wheat Grass in Thalassemic Children on Regular Blood Transfusion.

Authors:  Amit S Mutha; Kalpana U Shah; Aarti A Kinikar; Balasaheb B Ghongane
Journal:  Cureus       Date:  2018-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.